Sarasota, FL – According to filings with the U.S. Securities and Exchange Commission, Lakewood-Amedex is raising $40,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Steven Parkinson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lakewood-Amedex

Lakewood-Amedex is a privately held, clinical stage pharmaceutical company developing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called bisphosphocins. The rapid bactericidal action of this novel class of antimicrobials has been demonstrated against more than 70 different bacterial strains so far, including many antibiotic-resistant and biofilm forming bacteria. In the growing crisis of multidrug-resistant infections, Lakewood’s clinical development pipeline is focused on addressing the most life-threatening disease indications.

To learn more about Lakewood-Amedex, visit http://www.lakewoodamedex.com/

Contact:
Steven Parkinson, President and Chief Executive Officer
941-225-2515
sparkinson@lakewoodamedex.com
https://www.linkedin.com/in/steve-parkinson-2859836/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved